X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ASTRAZENECA PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ASTRAZENECA PHARMA TORRENT PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 45.1 178.3 25.3% View Chart
P/BV x 6.4 27.1 23.6% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
ASTRAZENECA PHARMA
Mar-14
TORRENT PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5501,285 120.6%   
Low Rs1,144634 180.4%   
Sales per share (Unadj.) Rs354.7189.6 187.1%  
Earnings per share (Unadj.) Rs40.1-0.2 -19,682.9%  
Cash flow per share (Unadj.) Rs64.23.8 1,670.5%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.168.6 397.9%  
Shares outstanding (eoy) m169.2225.00 676.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.85.1 75.0%   
Avg P/E ratio x33.6-4,712.7 -0.7%  
P/CF ratio (eoy) x21.0249.6 8.4%  
Price / Book Value ratio x4.914.0 35.3%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,89723,988 950.1%   
No. of employees `00014.71.6 942.9%   
Total wages/salary Rs m11,3531,605 707.5%   
Avg. sales/employee Rs Th4,083.03,040.2 134.3%   
Avg. wages/employee Rs Th772.31,029.2 75.0%   
Avg. net profit/employee Rs Th461.3-3.3 -14,129.6%   
INCOME DATA
Net Sales Rs m60,0214,740 1,266.3%  
Other income Rs m2,98892 3,244.7%   
Total revenues Rs m63,0094,832 1,304.0%   
Gross profit Rs m13,493-130 -10,394.8%  
Depreciation Rs m4,086101 4,037.5%   
Interest Rs m3,0850-   
Profit before tax Rs m9,310-139 -6,702.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m2,5295 49,679.8%   
Profit after tax Rs m6,781-5 -133,229.9%  
Gross profit margin %22.5-2.7 -820.9%  
Effective tax rate %27.2-3.7 -741.2%   
Net profit margin %11.3-0.1 -10,520.9%  
BALANCE SHEET DATA
Current assets Rs m52,6232,726 1,930.1%   
Current liabilities Rs m52,0222,435 2,136.4%   
Net working cap to sales %1.06.1 16.3%  
Current ratio x1.01.1 90.3%  
Inventory Days Days12074 162.1%  
Debtors Days Days7641 187.0%  
Net fixed assets Rs m85,0161,035 8,211.7%   
Share capital Rs m84650 1,692.4%   
"Free" reserves Rs m45,376942 4,814.9%   
Net worth Rs m46,2221,716 2,693.6%   
Long term debt Rs m41,1150-   
Total assets Rs m142,4324,156 3,427.1%  
Interest coverage x4.0NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.1 37.0%   
Return on assets %6.9-0.1 -5,655.9%  
Return on equity %14.7-0.3 -4,946.2%  
Return on capital %14.20-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m14,580375 3,892.2%   
Fx outflow Rs m3,600470 765.7%   
Net fx Rs m10,980-96 -11,491.6%   
CASH FLOW
From Operations Rs m8,942-8 -110,392.6%  
From Investments Rs m-47,070-146 32,305.8%  
From Financial Activity Rs m34,174862 3,963.6%  
Net Cashflow Rs m-3,655709 -515.9%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 0.3 2,340.0%  
FIIs % 12.6 15.7 80.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 9.1 96.7%  
Shareholders   26,511 12,856 206.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ORCHID PHARMA LTD  CIPLA  JUBILANT LIFE SCIENCES  VENUS REMEDIES  STERLING BIOTECH  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Energy and Metal Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours of trade and ended the day at their fresh record high levels.

Related Views on News

TORRENT PHARMA at All Time High; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Aug 20, 2018 | Updated on Aug 20, 2018

TORRENT PHARMA share price has hit an all time high at Rs 1,790 (up 0.2%). The BSE HEALTHCARE Index is up by 0.9%. Among the top gainers in the BSE HEALTHCARE Index today are TORRENT PHARMA (up 0.2%) and GSK PHARMA (up 1.6%). The top losers include SANOFI INDIA (down 0.2%) and ABBOTT INDIA (down 0.3%).

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 20, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - VENUS REMEDIES COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS